Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (1-10 of 181) with videos related to

Pageof 19
Sort By:
AIDS Reviews|November 7, 2013
Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapineDaniel Podzamczer
AIDS Reviews|December 22, 2012
The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapyArkaitz Imaz, Daniel Podzamczer
Enfermedades Infecciosas Y Microbiologia Clinica|April 11, 2015
[Mechanisms of action, pharmacology and interactions of dolutegravir]Esteban Ribera, Daniel Podzamczer
Expert Opinion on Pharmacotherapy|August 20, 2008
Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatmentPatricia Barragan, Daniel Podzamczer
Expert Review of Clinical Pharmacology|January 30, 2019
Switching strategies in the recent era of antiretroviral therapyPaula Prieto, Daniel Podzamczer
Expert Review of Anti-Infective Therapy|January 25, 2017
Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIVArkaitz Imaz, Daniel Podzamczer
Expert Opinion on Drug Metabolism & Toxicology|July 27, 2006
A review of nelfinavir for the treatment of HIV infectionMontserrat Olmo, Daniel Podzamczer
Expert Review of Anti-Infective Therapy|July 31, 2014
Switch strategies in antiretroviral therapy regimensEva Van den Eynde, Daniel Podzamczer
AIDS Reviews|January 16, 2007
Switching strategies to improve lipid profile and morphologic changesPatricia Barragan, Cesar Fisac, Daniel Podzamczer
Expert Opinion on Drug Safety|May 2, 2020
Nothing is perfect: the safety issues of integrase inhibitor regimensSofía Scévola, Juan Manuel Tiraboschi, Daniel Podzamczer
Pageof 19

Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
AIDS Reviews|November 7, 2013
Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapineDaniel Podzamczer
AIDS Reviews|December 22, 2012
The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapyArkaitz Imaz, Daniel Podzamczer
Enfermedades Infecciosas Y Microbiologia Clinica|April 11, 2015
[Mechanisms of action, pharmacology and interactions of dolutegravir]Esteban Ribera, Daniel Podzamczer
Expert Opinion on Pharmacotherapy|August 20, 2008
Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatmentPatricia Barragan, Daniel Podzamczer
Expert Review of Clinical Pharmacology|January 30, 2019
Switching strategies in the recent era of antiretroviral therapyPaula Prieto, Daniel Podzamczer
Expert Review of Anti-Infective Therapy|January 25, 2017
Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIVArkaitz Imaz, Daniel Podzamczer
Expert Opinion on Drug Metabolism & Toxicology|July 27, 2006
A review of nelfinavir for the treatment of HIV infectionMontserrat Olmo, Daniel Podzamczer
Expert Review of Anti-Infective Therapy|July 31, 2014
Switch strategies in antiretroviral therapy regimensEva Van den Eynde, Daniel Podzamczer
AIDS Reviews|January 16, 2007
Switching strategies to improve lipid profile and morphologic changesPatricia Barragan, Cesar Fisac, Daniel Podzamczer
Expert Opinion on Drug Safety|May 2, 2020
Nothing is perfect: the safety issues of integrase inhibitor regimensSofía Scévola, Juan Manuel Tiraboschi, Daniel Podzamczer
Pageof 19